OMONTYS Drug Patent Profile
✉ Email this page to a colleague
When do Omontys patents expire, and when can generic versions of Omontys launch?
Omontys is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are six patents protecting this drug.
This drug has one hundred and fourteen patent family members in thirty-four countries.
The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.
DrugPatentWatch® Generic Entry Outlook for Omontys
Omontys was eligible for patent challenges on March 27, 2016.
Indicators of Generic Entry
Summary for OMONTYS
International Patents: | 114 |
US Patents: | 6 |
Applicants: | 1 |
NDAs: | 1 |
Clinical Trials: | 18 |
Formulation / Manufacturing: | see details |
DailyMed Link: | OMONTYS at DailyMed |
Recent Clinical Trials for OMONTYS
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Amgen | Phase 4 |
Affymax | Phase 3 |
Takeda | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for OMONTYS
US Patents and Regulatory Information for OMONTYS
OMONTYS is protected by six US patents.
Patents protecting OMONTYS
Peptides that bind to the erythropoietin receptor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
Peptides that bind to the erythropoietin receptor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
Peptides that bind to the erythropoietin receptor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Erythropoietin receptor peptide formulations and uses
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
Spacer moiety for poly (ethylene glycol) modified peptide based compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Erythropoietin receptor peptide formulations and uses
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-005 | Mar 27, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-004 | Mar 27, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-006 | Mar 27, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for OMONTYS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Takeda Pharms Usa | OMONTYS | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-007 | Mar 27, 2012 | ⤷ Sign Up | ⤷ Sign Up |
Takeda Pharms Usa | OMONTYS | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-007 | Mar 27, 2012 | ⤷ Sign Up | ⤷ Sign Up |
Takeda Pharms Usa | OMONTYS | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-007 | Mar 27, 2012 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for OMONTYS
See the table below for patents covering OMONTYS around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
World Intellectual Property Organization (WIPO) | 2004100997 | ⤷ Sign Up | |
New Zealand | 543934 | Novel spacer moiety for poly (ethylene glycol)-modified peptide-based compounds | ⤷ Sign Up |
Japan | 2013173763 | ERYTHROPOITEIN RECEPTOR PEPTIDE FORMULATION AND USE | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |